1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

FLAME Shoots LABA/LAMA Combos Up To First Choice In COPD

 
• By Emily Hayes

At the American Thoracic Society annual meeting, science committee chair says change in COPD treatment guidelines to favor LABA/LAMA as preferred option will be considered soon.

SAN FRANCISCO – New data from Novartis AG's head-to-head FLAME study support wider use of LABA/LAMA combinations in at-risk patients for preventing exacerbations in COPD – in preference to a combination of a LABA with an inhaled corticosteroid – and could trigger a change in global guidelines for treatment, researchers say.

The FLAME study found that Novartis's once-daily Ultibro Breezehaler, which combines the long-acting beta agonist (LABA) indacaterol with the long-acting muscarinic antagonist (LAMA) glycopyrronium, was superior to GlaxoSmithKline PLC's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Canada Cuts Red Tape With Single Ethics Review For Trials

 
• By Neena Brizmohun

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

EMA Official Clarifies Benefits And Limitations Of Innovation Pathways

 
• By Eliza Slawther

A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

More from R&D

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 
• By Eliza Slawther

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.